Source:http://linkedlifedata.com/resource/pubmed/id/12386812
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
49
|
pubmed:dateCreated |
2002-10-18
|
pubmed:abstractText |
Lung cancer is a heterogeneous disease categorized into multiple subtypes of cancers which likely arise from distinct patterns of genetic alterations and disruptions. Precedent exists for a role of beta-catenin, a downstream component of the Wnt signaling pathway that serves as a transcriptional co-activator with TCF/LEF, in several human cancers including colon carcinomas. In this study, we observed that beta-catenin was highly and uniformly expressed in a panel of NSCLC cell lines and primary lung tumors. By contrast, gamma-catenin was weakly expressed or absent in several NSCLC cell lines and immunohistochemical analysis of primary NSCLC tumors revealed negligible to weak gamma-catenin staining in approximately 30% of the specimens. Treatment of NSCLC cells expressing reduced gamma-catenin protein with 5-aza-2'-deoxycytidine (5aza2dc), a DNA methylation inhibitor, or trichostatin A (TSA), a histone deacetylase inhibitor, increased gamma-catenin protein content in NSCLC cells with low gamma-catenin expression. Significantly, the activity of a beta-catenin/TCF-dependent luciferase reporter was markedly elevated in the NSCLC cell lines that underexpressed gamma-catenin relative to those lines that highly expressed gamma-catenin. Moreover, transfection of these cells with a gamma-catenin expression plasmid reduced the elevated TCF activity by 85% and strongly inhibited cell growth on tissue culture plastic as well as anchorage-independent growth in soft agar. This study shows that gamma-catenin can function as an inhibitor of beta-catenin/TCF-dependent gene transcription and highlights gamma-catenin as a potentially novel tumor suppressor protein in a subset of human NSCLC cancers.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/CTNNB1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cytoskeletal Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Desmoplakins,
http://linkedlifedata.com/resource/pubmed/chemical/JUP protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Trans-Activators,
http://linkedlifedata.com/resource/pubmed/chemical/beta Catenin,
http://linkedlifedata.com/resource/pubmed/chemical/gamma Catenin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0950-9232
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
24
|
pubmed:volume |
21
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
7497-506
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:12386812-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:12386812-Cell Division,
pubmed-meshheading:12386812-Cell Transformation, Neoplastic,
pubmed-meshheading:12386812-Cytoskeletal Proteins,
pubmed-meshheading:12386812-Desmoplakins,
pubmed-meshheading:12386812-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:12386812-Humans,
pubmed-meshheading:12386812-Lung Neoplasms,
pubmed-meshheading:12386812-Trans-Activators,
pubmed-meshheading:12386812-Tumor Cells, Cultured,
pubmed-meshheading:12386812-beta Catenin,
pubmed-meshheading:12386812-gamma Catenin
|
pubmed:year |
2002
|
pubmed:articleTitle |
gamma-Catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth.
|
pubmed:affiliation |
Veterans Administration Medical Center, Denver, Colorado, CO 80220, USA. robert.winn@uchsc.edu
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|